Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)
INR 1806.5
(0.3%)
INR 1806.5
(0.3%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 484.96 Billion | 432.78 Billion | 384.26 Billion | 331.39 Billion | 323.25 Billion | 286.86 Billion |
| Cost of Revenue | 226.48 Billion | 106.62 Billion | 117.07 Billion | 98.85 Billion | 104.71 Billion | 92.38 Billion |
| Gross Profit | 258.48 Billion | 326.16 Billion | 267.18 Billion | 232.53 Billion | 218.53 Billion | 194.47 Billion |
| Operating Expenses | 154.18 Billion | 233.73 Billion | 182.41 Billion | 168.35 Billion | 169.18 Billion | 147.22 Billion |
| Selling, General and Administrative Expenses | 122.9 Billion | 83.54 Billion | 54.68 Billion | 48.66 Billion | 53.1 Billion | 38.02 Billion |
| Research and Development Expenses | 31.27 Billion | 23.07 Billion | 21.32 Billion | 21.02 Billion | 19.25 Billion | 19.12 Billion |
| Other Expenses | - | 6.34 Billion | 569.5 Million | 656.8 Million | 1.13 Billion | 1.47 Billion |
| Cost and Expenses | 380.66 Billion | 340.35 Billion | 299.49 Billion | 267.21 Billion | 273.89 Billion | 239.61 Billion |
| Operating Income | 104.3 Billion | 93.04 Billion | 81.47 Billion | 64.27 Billion | 49.47 Billion | 47.37 Billion |
| Interest Expense | 2.38 Billion | 1.72 Billion | 1.27 Billion | 1.41 Billion | 2.9 Billion | 5.25 Billion |
| Income Tax Expense | 14.39 Billion | 8.47 Billion | 10.75 Billion | 5.14 Billion | 8.22 Billion | 6 Billion |
| Earnings before Tax | 110.87 Billion | 94.08 Billion | 44.81 Billion | 27.99 Billion | 50.09 Billion | 38.1 Billion |
| Net Income | 95.76 Billion | 84.73 Billion | 32.72 Billion | 29.03 Billion | 37.64 Billion | 26.65 Billion |
| Earnings Per Share Basic | 39.91 | 35.32 | 13.64 | 12.10 | 15.69 | 11.11 |
| Earnings Per Share Diluted | 39.91 | 35.32 | 13.64 | 12.10 | 15.69 | 11.11 |
| Weighted Average Shares Outstanding | 2.39 Billion | 2.39 Billion | 2.39 Billion | 2.39 Billion | 2.39 Billion | 2.39 Billion |
| Weighted Average Shares Outstanding (Diluted) | 2.39 Billion | 2.39 Billion | 2.39 Billion | 2.39 Billion | 2.39 Billion | 2.39 Billion |
| Gross Margin | 0.53 | 0.75 | 0.70 | 0.70 | 0.68 | 0.68 |
| EBIT Margin | 0.29 | 0.28 | 0.30 | 0.27 | 0.23 | 0.25 |
| Profit Margin | 0.20 | 0.20 | 0.09 | 0.09 | 0.12 | 0.09 |
| EBITDA | 138.36 Billion | 120.84 Billion | 66.99 Billion | 49.98 Billion | 73.12 Billion | 60.84 Billion |
| Earnings Before Tax Margin | 0.22 | 0.21 | 0.21 | 0.19 | 0.15 | 0.17 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 132.64 Billion | 126.52 Billion | 484.96 Billion | 119.82 Billion | 121.56 Billion | 120.03 Billion |
| Cost of Revenue | 26.94 Billion | 57.85 Billion | 226.48 Billion | 53.3 Billion | 27.36 Billion | 27.87 Billion |
| Gross Profit | 105.7 Billion | 68.67 Billion | 258.48 Billion | 66.52 Billion | 94.19 Billion | 92.16 Billion |
| Operating Expenses | 73.85 Billion | 38.64 Billion | 154.18 Billion | 42.11 Billion | 66.89 Billion | 66.35 Billion |
| Selling, General and Administrative Expenses | 35.45 Billion | 30.88 Billion | - | 33.19 Billion | 31.16 Billion | 30.71 Billion |
| Research and Development Expenses | 7.62 Billion | 7.76 Billion | - | 8.91 Billion | 8.11 Billion | 7.55 Billion |
| Other Expenses | 73.85 Billion | 5.32 Billion | 13.54 Billion | 6.05 Billion | 2.5 Billion | 2.93 Billion |
| Cost and Expenses | 100.79 Billion | 96.49 Billion | 380.66 Billion | 95.41 Billion | 94.26 Billion | 94.22 Billion |
| Operating Income | 31.84 Billion | 30.02 Billion | 104.3 Billion | 24.41 Billion | 31.04 Billion | 28.4 Billion |
| Interest Expense | 691.7 Million | 615.4 Million | 2.38 Billion | 735.7 Million | 347.3 Million | 492.9 Million |
| Income Tax Expense | 5.67 Billion | 5.52 Billion | 14.39 Billion | 1.48 Billion | 4.32 Billion | 3.9 Billion |
| Earnings before Tax | 35.97 Billion | 34.23 Billion | 110.87 Billion | 28.15 Billion | 30 Billion | 27.9 Billion |
| Net Income | 30.4 Billion | 28.35 Billion | 95.76 Billion | 26.54 Billion | 25.23 Billion | 23.75 Billion |
| Earnings Per Share Basic | 12.70 | 11.82 | - | 11.10 | 10.52 | 9.90 |
| Earnings Per Share Diluted | 12.70 | 11.82 | - | 11.10 | 10.52 | 9.90 |
| Weighted Average Shares Outstanding | 2.39 Billion | 2.39 Billion | 2.39 Billion | 2.39 Billion | 2.39 Billion | 2.39 Billion |
| Weighted Average Shares Outstanding (Diluted) | 2.39 Billion | 2.39 Billion | 2.39 Billion | 2.39 Billion | 2.39 Billion | 2.39 Billion |
| Gross Margin | 0.80 | 0.54 | 0.53 | 0.56 | 0.77 | 0.77 |
| EBIT Margin | 0.32 | 0.29 | - | 0.26 | 0.31 | 0.29 |
| Profit Margin | 0.23 | 0.22 | 0.20 | 0.22 | 0.21 | 0.20 |
| EBITDA | 42.92 Billion | 36.58 Billion | - | 30.91 Billion | 37.27 Billion | 34.72 Billion |
| Earnings Before Tax Margin | 0.24 | 0.24 | 0.22 | 0.20 | 0.26 | 0.24 |
CCR
HPBL
PGID
AAKASH
WA8
SESPF